Qurient (115180) Stock Overview

Qurient Co., Ltd., a biotech company, researches and develops drugs to address unmet medical needs in Korea. The company's pipeline products include Q301, which in Phase II clinical trial for the treatment of atopic dermatitis; Q203 that is in Phase II to treat drug resistant tuberculosis and covid-19 inflammation; and Q702, which is in phase I for the treatment of drug resistant NSCLC and immuno oncology. Its pipeline products also comprise 5LO inhibitor for asthma; and CDK7 inhibitor Q901 which is in pre-clinical stage for the treatment of solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is based in Seongnam, South Korea.